Trial Profile
An Open-label, Phase 2 Trial of Orally Administered PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma (GBM).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Dacomitinib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 21 May 2021 Results assessing liquid biopsy for patient stratification and monitoring of dacomitinib clinical trial in patients with EGFR amplified recurrent glioblastoma, presented at the 112th Annual Meeting of the American Association for Cancer Research
- 14 Aug 2018 Status changed from active, no longer recruiting to completed.
- 14 Aug 2018 Status changed from active, no longer recruiting to completed.